Treating Amyotrophic Lateral Sclerosis (ALS) With R(+) Pramipexole Dihydrochloride Monohydrate at 60 mg/Day

Bennett, James P., Jr., M.D., Ph.D.

Status

Conditions: Amyotrophic Lateral Sclerosis

Treatments: Drug: R(+) pramipexole dihydrochloride monohydrate

Study type: Expanded Access

Funder types: Other

Identifiers

NCT00596115

12316

Details and patient eligibility

About

R(+) pramipexole dihydrochloride monohydrate [R(+)PPX], an experimental neuroprotective drug, is provided in this open label extension study to ALS patients who have participated in earlier clinical protocols.

Sex: All

Ages: 30 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Definite diagnosis of ALS

Exclusion criteria

• No prior participation in R(+)PPX clinical studies